FindTrial
Sign In

Anti-CD19-CAR

BIOLOGICAL2 trials

Sponsors

Beijing Doing Biomedical Co., Ltd., Kecellitics Biotech Company Ltd

Conditions

LeukemiaLymphoma

Phase 1

Immunotherapy With CD19 CAR T-cells for B-Cell Lymphoma, ALL and CLL
NCT02546739
Beijing Doing Biomedical Co., Ltd.Leukemia, Lymphoma
Start: 2021-03-01End: 2023-03-01Target: 100Updated: 2021-01-26
Immunotherapy With CD19 CAR T-cells for B-Cell Leukemia
NCT04100187
Kecellitics Biotech Company LtdLeukemia
Start: 2023-02-01End: 2024-08-01Target: 100Updated: 2022-12-01

Related Papers

Factors Associated with Outcomes Among Refractory/Relapsed TP53-Mutated/Chromosome 17p Deletion Acute B-Cell Lymphoblastic Leukemia (B-ALL) Patients Treated with CD19-Targeted Chimeric Antigen Receptor (CAR)-T Therapy
Blood2021-11-053 citations
Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia.
2021-08-0736 citations
Factors Predicting Long-Term Survival Following CD19 CAR T-Cell Therapy in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
Blood2020-11-044 citations
Feasibility, and Efficacy of Donor-Derived cd19-Targeted Car t-Cell Therapy in Refractory/Relapsed(r/r)b-Cell Acute Lymphoblastic Leukemia (b-all) Patients
Blood2020-11-043 citations
Significant Long-Term Benefits of CAR T-Cell Therapy Followed By a Second Allo-HSCT for Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL) Patients Who Relapsed after an Initial Transplant
Blood2020-11-042 citations
Analysis of Factors Predicting Treatment Response of 254 Patients Who Received CD19-Targeted CAR-T Cell Therapy for Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Blood2019-11-134 citations